JAK-STAT通路在骨髓微环境中调控骨髓瘤细胞CD38表达:治疗意义
本研究探讨骨髓微环境中调节CD38表达及影响达雷妥尤单抗(DARA)介导抗体依赖细胞毒作用(ADCC)敏感性的可溶性因子。骨髓基质细胞培养上清(BMSC-sup)和白细胞介素-6(IL-6)下调CD38并降低DARA介导的ADCC;JAK-STAT3通路介导CD38下调,STAT1介导上调;JAK抑制剂芦可替尼抑制STAT3磷酸化、上调CD38并增强DARA介导的ADCC。
要点
- BMSC-sup和IL-6下调骨髓瘤细胞CD38表达并降低DARA介导的ADCC。
- JAK-STAT3通路介导CD38下调,JAK-STAT1通路介导CD38上调。
- 芦可替尼抑制STAT3磷酸化、上调CD38并增强DARA介导的ADCC。
核心结论
- 骨髓微环境中骨髓瘤细胞CD38表达受STAT1正向和STAT3负向调控。
- 抑制JAK-STAT3通路是增强CD38表达及抗CD38单抗介导骨髓瘤细胞毒作用的新型治疗选择。
研究设计与样本
- 研究检测骨髓微环境中调节CD38表达及与DARA介导ADCC敏感性相关的可溶性因子。
- 对BMSC-sup进行细胞因子谱分析,并在骨髓瘤细胞系中进行全基因组CRISPR-Cas9敲除筛选。
主要发现
- 原代BMSC培养上清和IL-6下调CD38表达并降低DARA介导的ADCC。
- 细胞因子谱分析和CRISPR-Cas9敲除筛选鉴定并验证JAK-STAT3通路介导CD38下调,JAK-STAT1通路介导CD38上调。
- STAT3敲低消除了BMSC-sup和IL-6诱导的骨髓瘤细胞系CD38下调。
- 原代骨髓瘤细胞中STAT3与CD38呈负相关。
- 芦可替尼抑制骨髓瘤细胞系STAT3磷酸化,上调骨髓瘤细胞系和原代患者骨髓瘤细胞CD38表达,并增强DARA介导的针对骨髓瘤细胞系的ADCC。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-CD38 monoclonal antibody (MoAb) treatments including daratumumab (DARA) are effective therapies for both newly diagnosed and relapsed multiple myeloma (MM). In this study, we examined the soluble factors that modulate CD38 expression and are associated with sensitivity to DARA-mediated antibody-dependent cellular cytotoxicity (ADCC) in the bone marrow (BM) microenvironment. Importantly, primary BM stromal cell (BMSC) culture supernatant (BMSC-sup) and interleukin-6 (IL-6) downregulated CD38 expression and reduced DARA-mediated ADCC. Both cytokine profiling of the BMSC-sup and genome-scale clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) knockout screening in MM cell lines identified and validated the JAK-STAT3 signaling pathway mediating CD38 downregulation, whereas the JAK-STAT1 pathway mediated CD38 upregulation. STAT3 knockdown abrogated BMSC-sup- and IL-6-induced CD38 downregulation on MM cell lines. We also confirmed that STAT3 and CD38 is negatively correlated in primary MM cells. To assess potential clinical relevance, pharmacological inhibition of the JAK-STAT pathway on BMSC-sup-induced CD38 downregulation was further examined. JAK inhibitor ruxolitinib inhibited STAT3 phosphorylation in MM cell lines, upregulated CD38 expression in MM cell lines and primary patient MM cells, and augmented DARA-mediated ADCC against MM cell lines. Taken together, our results suggest that CD38 expression on MM cells in the BM microenvironment is regulated by both STAT1 (positively) and STAT3 (negatively), and that inhibition of the JAK-STAT3 pathway represents a novel therapeutic option to enhance CD38 expression and anti-CD38 MoAb-mediated MM cytotoxicity.
引用
- Ogiya D, Liu J, Ohguchi H, et al. The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020. PMID: 32844992. doi:10.1182/blood.2019004332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。